Tenaya Therapeutics (Tenaya Therapeutics) Accounts Payable : $6.66 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Accounts Payable?

Tenaya Therapeutics's Accounts Payable for the quarter that ended in Mar. 2024 was $6.66 Mil.

Tenaya Therapeutics's quarterly Accounts Payable declined from Sep. 2023 ($5.90 Mil) to Dec. 2023 ($5.63 Mil) but then increased from Dec. 2023 ($5.63 Mil) to Mar. 2024 ($6.66 Mil).

Tenaya Therapeutics's annual Accounts Payable declined from Dec. 2021 ($10.72 Mil) to Dec. 2022 ($9.58 Mil) and declined from Dec. 2022 ($9.58 Mil) to Dec. 2023 ($5.63 Mil).

Tenaya Therapeutics Accounts Payable Historical Data

The historical data trend for Tenaya Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Accounts Payable Chart

Tenaya Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.60

1.02

10.72

9.58

5.63

Tenaya Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial													7.43	8.48	5.90	5.63	6.66

Tenaya Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Tenaya Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080

Website

https://www.tenayatherapeutics.com

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Executives

Timothy Hoey	officer: Chief Scientific Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson	officer: Chief Fin and Bus. Officer
Whittemore Tingley	officer: Chief Medical Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali	director, officer: Chief Executive Officer	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel	director, 10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs	director	TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava	director	C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc	director	1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019